Locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy plus concurrent weekly cisplatin with or without neoadjuvant chemotherapy.
- Author:
Chan Woo WEE
1
;
Bhumsuk KEAM
;
Dae Seog HEO
;
Myung Whun SUNG
;
Tae Bin WON
;
Hong Gyun WU
Author Information
- Publication Type:Original Article
- Keywords: Nasopharyngeal carcinoma; Intensity-modulated radiotherapy; Concurrent chemoradiotherapy; Induction chemotherapy
- MeSH: Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin*; Disease-Free Survival; Drug Therapy*; Follow-Up Studies; Humans; Induction Chemotherapy; Joints; Mucositis; Multivariate Analysis; Neoplasm Metastasis; Radiotherapy, Intensity-Modulated*; Survival Rate
- From:Radiation Oncology Journal 2015;33(2):98-108
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The outcomes of locoregionally advanced nasopharyngeal carcinoma patients treated with concurrent chemoradiation (CCRT) using intensity-modulated radiotherapy (IMRT) with/without neoadjuvant chemotherapy (NCT) were evaluated. MATERIALS AND METHODS: Eighty-three patients who underwent NCT followed by CCRT (49%) or CCRT with/without adjuvant chemotherapy (51%) were reviewed. To the gross tumor, 67.5 Gy was prescribed. Weekly cisplatin was used as concurrent chemotherapy. RESULTS: With a median follow-up of 49.4 months, the 5-year local control, regional control, distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival rates were 94.7%, 89.3%, 77.8%, 68.0%, and 81.8%, respectively. In multivariate analysis, the American Joint Committee on Cancer stage (p = 0.016) and N stage (p = 0.001) were negative factors for DMFS and DFS, respectively. Overall, NCT demonstrated no benefit and an increased risk of severe hematologic toxicity. However, compared to patients treated with CCRT alone, NCT showed potential of improving DMFS in stage IV patients. CONCLUSION: CCRT using IMRT resulted in excellent local control and survival outcome. Without evidence of survival benefit from phase III randomized trials, NCT should be carefully administered in locoregionally advanced nasopharyngeal carcinoma patients who are at high-risk of developing distant metastasis and radiotherapy-related mucositis. The results of ongoing trials are awaited.
